Devicor touts FDA nod for its next-gen breast biopsy system

Mass Device

The FDA approves Devicor's Mammotome revolve device, a less invasive dual vacuum-assisted biopsy system for sampling breast tissue.

Cincinnati, Ohio-based Devicor landed FDA approval for its Mammotome revolve biopsy system, a next-generation biopsy system designed to provide high quality tissue specimens while improving the efficiency of pre-biopsy planning time.

The Mammotome system features specimen management for collecting and organizing high quality individual tissue samples in numbered, as well as specimen radiograph and pathology-ready chambers to preserve tissue integrity. The less invasive DualVac vacuum technology also helps clinicians secure larger contiguous tissue samples, according to the press release.

Source URL (retrieved on *02/01/2015 - 9:47am*):
http://www.mdtmag.com/news/2012/12/devicor-touts-fda-nod-its-next-gen-breast-biopsy-system?qt-most_popular=0&qt-video_of_the_day=0&qt-recent_content=0